Search the Newsreel

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Class S

MACOM (MTSI) EPS and Revenue Review: The Available Earnings Metric Delivers a Beat on the Day; Market Reaction: The Stock Ends Down 10.58% in the Available Record - Earnings Beat Alert

MACOM (MTSI) EPS and Revenue Review: The Available Earnings Metric Delivers a Beat on the Day; Market Reaction: The Stock Ends Down 10.58% in the Available Record - Pre-Earnings Drift

MacroGenics (MGNX) Q1 2026 Results: The Bottom-Line Figure Beats Its Comparison in the Latest Session

Macro Metals: A new venture following the MinRes growth model

Madrigal (NASDAQ: MDGL) awards Reed 647 RSUs and options on 1,078 shares

Madrigal Pharmaceuticals (NASDAQ: MDGL) director John C. Reed was granted 647 restricted stock units (RSUs) and options on 1,078 shares. The RSUs will vest 50% on August 15, 2027, and 50% on August 15, 2028, while the stock options, with an exercise price of …

What's Going On With Cipher Pharmaceuticals Inc Stock Tuesday?

Amylyx (AMLX) Climbs to Fresh High as Avexitide Moves Closer to Commercialization

Amylyx Pharmaceuticals (AMLX) stock surged to a new three-year high following strong Phase 3 clinical trial results for its drug candidate Avexitide, a treatment for post-bariatric hypoglycemia (PBH). The drug successfully reduced low-blood-sugar episodes by 55% and met all secondary endpoints, leading to increased …

Banco Macro SA (BMA) Shares Fall 3.5% -- What GF Score of 67 Tells Investors

Banco Macro SA (BMA) shares dropped 3.5% to $76.08, reflecting a significant overvaluation according to GuruFocus' GF Value™, which estimates its intrinsic value at $32.20. Despite an above-average GF Score™ of 67/100, BMA shows strong momentum and growth but weak financial strength and very …

JALL3 - Jalles Machado - Resultados, Dividendos, Cotação e Indicadores

Aurinia (AUPH) Earnings Metrics: EPS Comes in Above Forecast in the Current Update; Trading-Day Reaction: Shares Move 0.07% Up - Quarterly Profit Report

Titan (TITN) Earnings Numbers in Focus: The Bottom-Line Figure Beats Its Comparison at the Close; Price Action: Shares Finish 2.26% Lower in the Current Update - Negative Surprise Momentum

Will IBM’s US$240 Million OpenAI and Together AI Bet Change International Business Machines' (IBM) Narrative?

Supernus Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:SUPN)

Recursion (NASDAQ: RXRX) CSO sees 26K shares withheld for taxes

Recursion Pharmaceuticals (NASDAQ: RXRX) Chief Scientific Officer David Hallett had 26,657 shares of Class A common stock withheld on August 17, 2026, to satisfy tax obligations related to the net settlement of restricted stock units. This action was solely for tax purposes and not …

Verrica Pharmaceuticals (NASDAQ:VRCA) CMO Noah Rosenberg Purchases 4,200 Shares of Stock

Verrica Pharmaceuticals' (NASDAQ:VRCA) Chief Marketing Officer, Noah Rosenberg, purchased 4,200 shares of the company's stock for $20,622, increasing his direct ownership by 178.19%. This transaction occurred as VRCA shares traded down, below their 50-day and 200-day moving averages. The company holds an $80.4 million …

Verrica Pharmaceuticals (NASDAQ:VRCA) CEO Jayson Rieger Acquires 5,000 Shares

Verrica Pharmaceuticals CEO Jayson Rieger recently purchased 5,000 shares of the company's stock for $24,550, increasing his total ownership to 207,593 shares. This transaction occurred as the stock fell 4.3% to $4.68, bringing its market capitalization to approximately $80.4 million. The company has mixed …

VRCA Looks 50.3% Undervalued on GF Value™ Despite Profitability Challenges

Verrica Pharmaceuticals Inc (NASDAQ: VRCA) saw its CEO purchase 25,000 shares, leading to a 7.5% after-hours price increase and renewed investor interest despite ongoing profitability challenges. While the GF Value™ suggests VRCA is 50.3% undervalued, this should be viewed cautiously given the company's negative …

International Business Machines (NYSE:IBM) Shares Up 1.7% - Should You Buy?

International Business Machines (IBM) shares rose 1.7% in mid-day trading but with lower-than-average volume. Despite risks like weak mainframe performance and a securities fraud investigation, growth catalysts include Maximo software adoption and enterprise AI momentum. Analysts maintain a "Moderate Buy" consensus with a $265.40 …

Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors

Corbus Pharmaceuticals Holdings Inc. (CRBP) stock dropped 3.91% on Tuesday, closing at $10.08. This underperformance occurred during a general market downturn, with both the NASDAQ Composite Index and Dow Jones Industrial Average also experiencing losses. The decline ended a five-day winning streak for the …

Arrowhead (NASDAQ: ARWR) director to sell 2,000 shares

A director at Arrowhead Pharmaceuticals Inc. (ARWR), Adeoye Olukotun, has filed a Rule 144 notice to sell 2,000 shares of common stock through Merrill Lynch. The proposed sale, valued at $173,876.47, is expected around August 18, 2026, on NASDAQ. These shares were originally acquired …

Mirum Pharma (NASDAQ: MIRM) officer lines up $4M share sale

Jolanda Marie Howe, an officer at Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), has filed a Form 144 to sell 40,000 common shares valued at $4,000,000.00 on August 18, 2026, following a stock option exercise. The sale will be executed through Morgan Stanley Smith Barney. The …

Processa Pharmaceuticals (NASDAQ: PCSA) gains new 5.8% owner with no sole control

Soleus Capital Master Fund, L.P. and related entities, including Guy Levy, have reported a beneficial ownership of 160,943 shares of Processa Pharmaceuticals (PCSA), representing 5.8% of the outstanding common stock. This ownership grants shared voting and dispositive power but no sole control. The filing …

Rhythm (RYTM) CMO reports no company stock holdings

Rhythm Pharmaceuticals, Inc. (RYTM) Chief Medical Officer, Joshi Manher, has filed an initial statement of beneficial ownership (Form 3) indicating no equity transactions or holdings in the company. The filing includes an Exhibit 24 for a Power of Attorney, allowing filings to be made …

Rhythm Pharmaceuticals (RYTM) grants CMO 50K options expiring 2036

Rhythm Pharmaceuticals (RYTM) has granted its Chief Medical Officer, Manher Joshi, 50,000 stock options with an exercise price of $115.44, expiring in 2036, and 25,000 Restricted Stock Units (RSUs). The stock options vest over four years, while the RSUs vest annually from 2027 to …

Recursion Pharmaceuticals Inc (RXRX) News, Articles, Events & Latest Updates

MIRA (MIRA) Financial Results: The Company Lists Its Latest Available Figures in the Latest Session; Investor Response: Shares Fall 3.16% in the Latest Reading - Segment Revenue Breakdown

BioMarin looks to spur growth with potential $490M buyout of Dutch bone drug company

BioMarin Pharmaceutical is reportedly looking to acquire Dutch bone drug company Alesa Therapeutics for up to $490 million, including a $275 million upfront payment. This potential acquisition comes shortly after BioMarin decided to halt the late-stage development of another drug. The move is seen …

Verrica (NASDAQ: VRCA) CEO buys 25,000 shares in August

Verrica Pharmaceuticals Inc. (VRCA) CEO Jayson Rieger purchased 25,000 shares of common stock in August 2026. These open-market transactions included 5,000 shares bought on August 17 at $4.91 per share and 20,000 shares on August 14 at a weighted average price of $5.06. The …

Verrica (NASDAQ: VRCA) interim CFO adds 5,000 shares in open-market buy

Verrica Pharmaceuticals Inc.'s Interim CFO, John J. Kirby, purchased 5,000 shares of common stock in the open market on August 18, 2026. The shares were bought at a weighted average price of $4.93, with individual trades ranging from $4.85 to $4.99 per share. Following …

LUCIDITY Shows Clear Phase III Win For Amylyx’s Avexitide

Amylyx's Avexitide achieved a clear Phase III win in the LUCIDITY trial for patients with post-bariatric hypoglycemia (PBH). The company plans to submit the drug to the US FDA by the end of 2026. This positive outcome follows a previous late-stage drug failure for …

Why Xeris Biopharma (XERS) Is Up 6.6% After Tighter 2026 Revenue Guidance And Wider Losses

International Business Machines Corp. stock outperforms competitors on strong trading day

International Business Machines Corp. (IBM) shares rose 1.67% to $232.67 on Tuesday, outperforming the broader market which saw the S&P 500 Index fall 0.69% and the Dow Jones Industrial Average fall 0.22%. This gain broke a two-day losing streak for the stock.

These 2 Stocks Are Setting Off Technical Alarm Bells with $1,000+ Price Tags. Here’s the Company I’d Bet on for the Long Term.

Buy Sell cards by Kelly Sikkema via Unsplash Virginia-based conglomerate Graham Holdings (GHC)was one of Barchart's 200 bearish price surprises in Monday trading. It was down 2.2% on the day to $1,165.29; its standard deviation was -1.67, far from the highest, Eyepoint (EYPT), at …

MacroGenics (MGNX) exec adds 40K shares via option exercise

MacroGenics (MGNX) Senior VP, Research & CSO Ezio Bonvini, reported exercising 40,000 employee stock options at $2.60 per share on August 17, 2026, and holding the acquired common stock. Following this transaction, Bonvini directly holds 185,799 shares of common stock and 88,000 employee stock …

Rocket Pharma (NASDAQ: RCKT) sale tied to 2026 vesting, tax bill

Gaurav Shah, associated with Rocket Pharmaceuticals (RCKT), has filed a Rule 144 notice to sell 2,293 shares of restricted common stock. This proposed sale is linked to restricted stock vesting on August 14, 2026, and partially aims to cover a tax obligation from a …